Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
The company puts its faith in a new lymphodepletion regimen to overcome mediocre early results with its lead Car-NK therapy.
Having impressed two years ago, Dizal returns with even more comprehensive targeted therapy data.
Toxicity casts a shadow over vorasidenib’s prospects as possibly the first targeted therapy for low-grade glioma.
Asco data suggest that the TROP2 ADC Merck & Co licensed from Kelun is at least as good as Gilead and Astra/Daiichi’s assets.
After generating unexpectedly positive TIGIT data Roche moves to launch a phase 3 trial.
Excluding BRCA-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer, Astra’s Duo-O suggests.